GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2025
0mins
Should l Buy ?
Source: Newsfilter
GlycoMimetics Merger and Stock Split: GlycoMimetics' stockholders approved a merger with Crescent Biopharma and a 1-for-100 reverse stock split, which will reduce outstanding shares from approximately 64.5 million to about 0.6 million. The combined company is expected to trade under the name "Crescent Biopharma, Inc." on Nasdaq starting June 16, 2025.
Company Backgrounds: GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, while Crescent Biopharma is advancing precision-engineered molecules for solid tumors, including a lead program targeting PD-1 and VEGF pathways.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
